About this event
The future of diabetes treatment is rapidly evolving, and one of the promising developments is the innovations around artificial pancreas. Artificial pancreas (also known as an automated insulin-delivery system, closed-loop system, or bionic pancreas) constitutes a system that combines real-time glucose monitoring, artificial intelligence (AI), and automated insulin delivery to provide more precise and efficient management of diabetes. The above three components in an artificial pancreas work together to mimic a healthy pancreas in controlling blood glucose in the body and are mainly used to help people with type 1 diabetes. There are several types of artificial pancreas systems, such as threshold suspend and predictive suspend systems, insulin-only systems, and dual hormone systems.
Artificial pancreas technology has the potential to revolutionize diabetes treatment by providing a more personalized and automated approach to insulin delivery and offers solutions for various day-to-day challenges for patients, such as improved glucose control, personalized insulin delivery, increased safety, reduced time in hypoglycemia and better control during the night, making it suitable for all ages to improve their quality of life.
While the Artificial Pancreas has shown promise, it is not yet considered mainstream in diabetes treatment. Challenges such as cost, accessibility, accommodation of unique variations in insulin sensitivity for individuals, accuracy and reliability of CGM systems and insulin pumps, integration of devices, and regulatory barriers have limited its widespread adoption. However, as technology continues to evolve, addressing these challenges and demonstrating its long-term benefits, there is potential for the Artificial Pancreas to become a mainstream treatment option for individuals with diabetes. As research and development progresses, we can expect to see further advancements in this area, leading to more effective and accessible diabetes treatment options. Some of the major products are Tandem Control-IQ, Insulet Omnipod Horizon, Diabeloop DBLG1, and Beta Bionics iLet.
Join our webinar to learn more about:
I'm passionate about technology innovation and how it will shape the Future of the Life Sciences industry. I work with the client stakeholders from R&D, Innovation, Strategy, and BD&L to provide deep techno-commercial insights.
I am a Ph.D. in Pharmaceutical Sciences and have extensively been associated with clients looking for innovation, strategies, business, and sustainability in the field of Medical devices, diagnostics, and pharmaceuticals
FutureBridge is a techno-commercial consulting and advisory company.
We track and advise on the future of industries from a 1-to-25-year perspective to keep you ahead of the technology curve, propel your growth, Identify new opportunities, markets and business models, answer your unknowns, and fac
Share this event